
About Sunshine Biopharma
Sunshine Biopharma (NASDAQ:SBFM) is a dynamic entity engaged in the development of innovative pharmaceuticals aimed at treating cancer and other acute medical conditions. This company is distinguished by its commitment to advancing research and development in the pharmaceutical field, focusing on creating drugs that target the unmet needs of patients battling serious diseases. Sunshine Biopharma's efforts are driven by a goal to bring groundbreaking treatments from the lab bench to the bedside, demonstrating an unwavering dedication to improving patient outcomes. The company's operations span across the intricate landscape of pharmaceutical research, showcasing a robust pipeline of projects that promise to redefine therapeutic approaches in oncology and beyond. Through its relentless pursuit of excellence in healthcare innovation, Sunshine Biopharma strives to achieve its objectives of providing new, effective options for treatment and advancing the global pharmaceutical industry.
Snapshot
Operations
Products and/or services of Sunshine Biopharma
- Adva-27a, a unique anticancer compound targeting multidrug-resistant cancers.
- Generic version of the anticancer drug Plitidepsin to treat COVID-19 in collaboration with the University of Georgia.
- Development of novel small molecules for targeted therapy of various cancers.
- Research into Coronavirus treatments including COVID-19, focusing on new therapeutic approaches.
- Manufacturing and distribution of essential generic pharmaceuticals for various conditions.
- Exploration of potential treatments for other viral diseases beyond COVID-19, leveraging their expertise in virology.
Sunshine Biopharma executive team
- Dr. Steve N. Slilaty Ph.D.Chairman, President & CEO
- Mr. Camille SebaalyCFO, Secretary & Director
- Mr. Malek ChamounChief Development Officer
- Mr. Michel RoyChief Commercial Officer
- Mr. Robert G. FerreiraPresident of Sunshine Bio Investments Inc